Philip Laws

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis

Zenas Z N Yiu, G Becher, Brian Kirby et al. · JAMA Dermatology · 2022 · 144 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

No Deaths Associated with Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose

David Wampler, D. Kimberley Molina, John McManus et al. · Prehospital Emergency Care · 2011 · 105 citations

Pharmacy, Emergency Medical Services, Emergency Medicine +14

IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis

Charlie Bridgewood, Gareth W. Fearnley, Anna Berekméri et al. · Frontiers in Immunology · 2018 · 83 citations · Full text

Life Sciences, Dermatology, Immunology +16

Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers

L. M. Carter, Zoe Wigston, Philip Laws et al. · British Journal of Dermatology · 2023 · 78 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Childhood Mycosis Fungoides: Experience of 28 Patients and Response to Phototherapy

Philip Laws, Neil H. Shear, Elena Pope · Pediatric Dermatology · 2014 · 68 citations

Medicine, Dermatology, Oncology +15